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Abstract
Breast cancer (BC) is the most common newly diagnosed cancer among
women in Trinidad and Tobago (TT) and BC mortality rates are among the
highest in the world. Globally, racial/ethnic trends in BC incidence, mortality
and survival have been reported. However, such investigations have not been
conducted in TT, which has been noted for its rich diversity. In this study,
we investigated associations among ancestry, geography and BC incidence,
mortality and survival in TT. Data on 3767 incident BC cases, reported to
the National Cancer Registry of TT, from 1995 to 2007, were analyzed in
this study. Women of African ancestry had significantly higher BC incidence
and mortality rates (Incidence: 66.96; Mortality: 30.82 per 100,000) compared
to women of East Indian (Incidence: 41.04, Mortality: 14.19 per 100,000) or
mixed ancestry (Incidence: 36.72, Mortality: 13.80 per 100,000). Geographically, women residing in the North West Regional Health Authority (RHA)
catchment area followed by the North Central RHA exhibited the highest
incidence and mortality rates. Notable a ncestral differences in survival were
also observed. Women of East Indian and mixed ancestry experienced significantly longer survival than those of African ancestry. Differences in survival
by geography were not observed. In TT, ancestry and geographical residence
seem to be strong predictors of BC incidence and mortality rates. Additionally, disparities in survival by ancestry were found. These data should be
considered in the design and implementation of strategies to reduce BC incidence and mortality rates in TT.
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Introduction
As the most commonly diagnosed malignancy among
women worldwide, breast cancer (BC) is clearly a major
global health concern. The most recent data from the
International Agency for Research on Cancer (IARC)
estimated that 1.67 million incident BC cases were diagnosed
in 2012 [1]. While age-standardized incidence rates vary
extensively, approximately 53% of all incident BC cases
occurred in economically developing countries. Globally,
BC is the fifth most common cause of cancer mortality;
whereas, in developed countries, it is the second leading
cause of mortality among women, in economically
developing countries this malignancy is the most prevalent
cause of cancer mortality [1].
The vast majority of studies to date have focused on
BC in developed countries, where incidence and mortality
rates have demonstrated a decreasing trend (or at least
remaining stable in many countries). In contrast, studies
are limited among many developing countries, where
incidence and mortality are projected to continually increase in the next few decades [2–5]. This is particularly
pronounced in developing countries of the Caribbean
where population growth, aging, increasing life expectancy
[5], and the adoption of “westernized” lifestyles, are
identified as possible contributing factors to the increasing incidence [3, 6, 7]. Furthermore, lack of access to
adequate comprehensive breast care, including mammography and timely, appropriate treatment and followup care, may contribute to increases in BC mortality

[8, 9].
One such country is the English-speaking Republic of
Trinidad and Tobago (TT) situated in the Southern
Caribbean (just northeast of Venezuela). Designated by
the World Bank [10] as a high-income economy, given
that it has a gross national income (GNI) of ≥$12,746,
TT has not reached the final stage of development.
Nonetheless, TT is the most industrialized of all Caribbean
nations, with oil, natural gas, chemical industries, and
food and beverage industries, and has recently experienced
an 8% economic growth, more than double the regional
average [11]. As of 2011 [12], TT had a population of
1,328,019, with diverse self-reported ancestries, including
East Indian (35%), African (34%), mixed (23%; [African/
East Indian, 8% and mixed/other, 15%]), other (<1%),
and unknown ancestries (6%) [12].
The Ministry of Health is the national authority
responsible for oversight of the national healthcare system.
There are five Regional Health Authorities (RHAs) that
are responsible for the provision of healthcare services in
their respective geographic catchment area. Cancer screening and treatment services are provided free to all citizens
of TT at six public medical facilities. Furthermore, the
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Chronic Disease Assistance Programme provides free
oncology prescription drugs.
Despite the opportunities afforded by universal healthcare in TT, BC mortality rates are among the highest in
the Caribbean and the world [13–16]. A recent study by
Camacho-Rivera and colleagues [16], indicated that women
in TT are diagnosed with BC at a later stage and initiate/
receive multi-mode therapy (i.e., combination of ≥2 types
of treatment) for their disease at very low levels [16].
Utilizing data from the National Cancer Registry of TT,
on incident BC cases diagnosed between January 1995
and December 2007, we sought to expand upon the findings of Camacho-
Rivera and colleagues [16], with the
objective of investigating associations among ancestry,
geography and BC incidence, mortality and survival in
TT. Findings from this study will be integral to understanding some of the factors associated with the poor
outcomes observed among BC patients in TT.

Materials and Methods
Study design and measures
This study included incident, invasive BC cases among
female patients reported to the National Cancer Registry
of TT. Prospectively collected tumor incidence and mortality data from January 1, 1995 and December 31, 2007
were included in the analysis. The population-based cancer
registry was established in 1994 by the Trinidad and
Tobago Cancer Society, using cancer registry guidelines
set by IARC [17, 18]. This registry uses the CANREG
database and statistical software (Version 4.33). Records
from both public and private biomedical institutions
populated the registry dataset. Public sector institutions
included Port of Spain General Hospital, Caura Hospital,
National Radiotherapy Center, Sangre Grande Hospital,
Tobago Regional Hospital, Mount Hope Women’s
Hospital, Eric Williams Medical Sciences Complex, San
Fernando Hospital, Point Fortin Area Hospital, and the
Central Statistical Office. Private sector data sources included Augustus Long Hospital, Petrotrin-
Santa Flora
Medical Centre, Community Hospital of the Seven Day
Adventists, Brian Lara Treatment Centre, and Westshore
Private Hospital.
In Trinidad, there is a local government system with
five Municipal Corporations for the cities of Port of Spain
and San Fernando, and the boroughs of Arima, Point
Fortin and Chaguanas, as well as nine Regional
Corporations (including those of: (1) Couva, Tabaquite,
and Talparo; (2) Diego Martin; (3) Mayaro and Rio Claro;
(4) Penal and Debe; (5) Princes Town; (6) Sangre Grande;
(7) San Juan and Laventille; (8) Siparia; and (9) Tunapuna
and Piarco) (Fig. 1). Tobago is administratively controlled
1743
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Figure 1. Geospatial maps of breast cancer incidents and mortality rates in Trinidad and Tobago 1995–2007: (A–B) age-standardized rates for all
corporations, and (C–D) age-standardized rates for all Regional Health Authorities.

by the Tobago House of Assembly. The geographical area
of residence data from the cancer registry was aligned
with the corresponding Ministry of Health RHAs, which
provides healthcare personnel and facilities for persons
residing in the catchment area. The North West Regional
Health Authority (NWRHA); North Central Regional
Health Authority (NCRHA); South West Regional Health
Authority (SWRHA); Eastern Regional Health Authority
(ERHA) and Tobago Regional Health Authority (TRHA)
are responsible for direct provision of healthcare services
in their respective catchment area. However, there are
specialized cancer centers in various RHAs that can be
accessed with a doctor’s referral without regard to the
patient’s place of residence.
In the registry data file, demographic characteristics (age
at diagnosis and ancestry) were self-reported. Four ancestry
groups are most prevalent among the population of TT:
1744

African, East Indian, mixed, and other. Imputation was
used to ascribe ancestry among cancer cases with unknown/
missing ancestry (n = 5301 [21.2%]) [19]. Essentially,
four separate predictive binary logistic regression models
were calculated. Ancestry was used as the dependent variable for estimation purposes. Known demographic variables
including: gender, age, and residence (15 corporations and
boroughs used as dummy variables) were used as independent variables in the four predictive regression models
to assign ancestry based on known profiles from all instances
of self-
reporting data. After fitting the four models for
the cases with missing ancestry data, probabilities of
predicted values of ancestry were calculated. These values
revealed the probability of each cancer patient’s placement
into each of the four ancestry groups. Cancer patients
with missing ancestry were then assigned to one of the
four ancestry groups according to the highest probability

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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of being a member of that group. Using this method, all
of the cases with unknown/missing ancestry were assigned
to either the African or East Indian ancestry group as
the other probabilities were significantly lower and would
have increased the errors of estimation.
Clinical data (stage, grade, histology, and treatment
modalities) were classified based on WHO International
Classification of Disease (ICD-O-3) codes. Female BC cases
with missing data and/or data errors (e.g., date of death
before date of incident BC, no date of last follow-up, etc.)
were excluded (n = 10). The analytic dataset consisted of
3767 incident invasive BC cases. This study received approval
by Institutional Review Boards of all participating
institutions.

Statistical analysis
Study sample characteristics overall and indexed by ancestry were described using frequencies and proportions.
Chi-square and Fisher’s exact tests were used to compare
sample characteristics by ancestry. Crude incidence and
mortality rates in TT were estimated using population
data from the TT 2000 and 2010 census [12]. From these
estimates, we calculated the age-
standardized incidence
and mortality rates (per 100,000) based on the world-
standardized population weights [20], to better compare
BC rates in TT to global trends. Populations of corporations in the other years were estimated through interpolation using the “irregular points of year” estimation method
[17, 18]. Cox proportional hazards models were used to
calculate the hazard ratios (HR) and 95% confidence
intervals (CIs) of BC mortality by ancestry and by geography. In the initial model, we adjusted for age at BC
diagnosis only. In the multivariable-
adjusted model, we
further adjusted for marital status, mode of detection,
cancer stage, and whether any BC treatment was received.
All reported P-
values are two-
sided and P < 0.05 was
considered statistically significant. Analyses were done using Statistical Package of Social Science V.20 (SPSS) (IBM
Corporation, Valhalla, NY) and R Statistical Software (R
Foundation, Vienna, Austria).

Results
Characteristics of incident BC cases in
Trinidad and Tobago
Data are reported on 3767 incident primary BC cases (54%
of African ancestry, 33% of Indian ancestry, and 13% of
mixed ancestry) reported to the TT cancer registry between
January 1, 1995 and December 31, 2007. As shown in
Table 1, overall the mean age at diagnosis was 56 years,
with significant differences by ancestry. Specifically, women

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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of Indian ancestry presented at a younger age, compared
to women of African ancestry or mixed ancestry (P < 0.01).
In terms of clinical characteristics, localized stage
(39.93%) was most frequent, followed by regional (33.66%)
and distant (8.57%) stages, with the highest frequency
of BC patients diagnosed with localized cancer observed
among women of Indian ancestry (P < 0.01). Although
there were substantial ‘unspecified’ data on tumor grade
(78% overall), women of mixed ancestry were more
frequently diagnosed with poorly differentiated tumors

and least likely to be diagnosed with well-differentiated
tumors, compared to women of African or Indian ancestry
(P < 0.01). Histologically, adenocarcinoma or carcinoma,
not otherwise specified were diagnosed less frequently
among women of mixed ancestry (32.14%), compared
to women of Indian (37.24%) or African ancestry (39.26%;
P < 0.01). There were significant differences in the receipt
of surgical treatment and initiation of chemotherapy,
radiation therapy, hormone therapy, and immunotherapy
by ancestry; specifically, women of African ancestry were
least likely to have received/initiated any BC treatment
compared to women of Indian and mixed ancestry (all
P < 0.01). At the time of last contact (1997–2007), the
largest proportion of cases still alive were of Indian
ancestry (67.58%), followed by those of mixed ancestry
(64.47%), and lastly, African ancestry (56.49%).

Breast cancer incidence, mortality, and
survival in Trinidad and Tobago
Overall, women of African ancestry had the highest age-
standardized BC incidence rates per 100,000, followed
by women of Indian and mixed ancestry (African ancestry:
66.96, 95% CI 63.95–65.97; Indian ancestry: 41.04, 95%
CI 38.75–43.34; and mixed ancestry: 36.72, 95% CI
33.39–40.03). Women of African ancestry also had the
highest age-
standardized BC mortality rates (30.82 per
100,000, 95% CI 28.80–32.84), followed by women of
Indian ancestry (14.19 per 100,000, 95% CI 12.84–15.54)
and mixed ancestry (13.80 per 100,000, 95% CI
11.79–15.81).
As shown in Figure 1, BC incidence and mortality rates
were highest in the NWRHA geographic region. In
NWRHA, incidence and mortality rates were 53.82 and
23.52 per 100,000, respectively; the nation’s capital city
of Port-of-Spain had the highest rates of both incidence
(75.19 per 100,000) and mortality (36.12 per 100,000).
In NCRHA, incidence and mortality rates were 45.78 per
100,000 and 18.72 per 100,000, respectively; the corporation of Arima had the incidence (66.13 per 100,000) and
mortality rates (27.34 per 100,000). In TRHA, incidence
and mortality rates were 43.44 and 19.97 per 100,000;
the parish of St. David had the highest incidence (58.60
1745
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Table 1. Characteristics of incident breast cancer cases reported to the cancer registry, overall and by ethnicity, Trinidad and Tobago, 1995–2007.

Characteristics
Demographic characteristics
Age at diagnosis (years),
mean ± SD
Age at diagnosis (years)
<45
45–60
>60
Marital status
Divorced/separated/widowed
Married/living as married
Single/never married
Unspecified
Geographic area of residence2
Eastern
North Central
North West
South West
Tobago
Unknown
Clinical characteristics
Mode of detection
Clinical diagnosis
Incidental finding at autopsy
Unknown/missing
Stage at diagnosis
Localized
Regional
Distant
Unknown
Grade
Grade I – Well differentiated
Grade II – Moderately
  Differentiated
Grade III – Poorly
  Differentiated
Grade IV – Undifferentiated
Unspecified
Histology
Adenocarcinoma
Carcinoma NOS
Other
Surgical treatment received
Yes
No
Missing
Chemotherapy initiated
Yes
No
Missing
Radiation therapy initiated
Yes
No
Missing
Hormone therapy initiated
Yes
No
Missing

Overall N = 3767
n (%)

African n = 2020
n (%)

Indian n = 1246
n (%)

Mixed n = 501
n (%)

P1

56.55 ± 14.63

57.46 ± 15.29

54.29 ± 13.00

58.48 ± 15.10

<0.01

856 (22.72)
1489 (39.53)
1422 (37.75)

451 (22.33)
743 (36.78)
826 (40.89)

307 (24.64)
544 (43.66)
395 (31.70)

98 (19.56)
202 (40.32)
201 (40.12)

<0.01

727 (19.30)
1669 (44.31)
744 (19.75)
627 (16.64)

375 (18.56)
751 (37.18)
499 (24.70)
395 (19.55)

240 (19.26)
693 (55.62)
133 (10.67)
180 (14.45)

112 (22.36)
225 (44.91)
112 (22.36)
52 (10.38)

<0.01

194 (5.15)
915 (24.29)
1314 (34.88)
1175 (31.19)
165 (4.38)
4 (0.11)

100 (4.95)
457 (22.62)
866 (42.87)
442 (21.88)
152 (7.52)
3 (0.15)

68 (5.46)
333 (26.73)
195 (15.65)
643 (51.61)
6 (0.48)
1 (0.08)

26 (5.19)
125 (24.95)
253 (50.50)
90 (17.96)
7 (1.40)
0 (0.00)

<0.01

1601 (42.5)
2 (0.05)
2164 (57.45)

849 (42.30)
2 (0.10)
1156 (57.60)

534 (42.35)
0 (0.00)
727 (57.65)

218 (41.52)
0 (0.00)
281 (56.31)

<0.01

1504 (39.93)
1268 (33.66)
323 (8.57)
672 (17.84)

768 (38.02)
652 (32.28)
202 (10.00)
398 (19.70)

530 (42.54)
430 (34.51)
79 (6.34)
207 (16.61)

206 (41.12)
186 (37.13)
42 (8.38)
67 (13.37)

<0.01

68 (1.81)
175 (4.65)

37 (1.83)
97 (4.80)

30 (2.41)
56 (4.49)

1 (0.20)
22 (4.39)

<0.01

467 (12.40)

256 (12.67)

127 (10.19)

84 (16.77)

116 (3.08)
2941 (78.07)

49 (2.43)
1581 (78.27)

57 (4.57)
976 (78.33)

10 (2.00)
384 (76.65)

350 (9.29)
1068 (28.35)
2349 (62.36)

164 (8.12)
629 (31.14)
1227 (60.74)

158 (12.68)
306 (24.56)
782 (62.76)

28 (5.59)
133 (26.55)
340 (67.86)

<0.01

2778 (73.75)
502 (13.33)
487 (12.92)

1404 (69.50)
311 (15.40
305 (15.10)

984 (78.97)
125 (10.03)
137 (11.00)

390 (77.84)
66 (13.17)
45 (8.99)

<0.01

1576 (41.84)
1699 (45.10)
492 (13.16)

779 (38.56)
933 (46.19)
308 (15.25)

567 (45.50)
542 (43.50)
137 (11.00)

230 (45.91)
224 (44.71)
47 (9.38)

<0.01

1355 (35.97)
1259 (33.42)
1153 (30.61)

692 (34.26)
688 (34.06)
640 (31.68)

433 (34.75)
423 (33.95)
390 (31.30)

230 (45.91)
148 (29.54)
123 (24.55)

<0.01

1282 (34.03)
1995 (52.96)
490 (13.01)

647 (32.03)
1067 (52.82)
306 (15.15)

451 (36.20)
658 (52.81)
137 (11.00)

184 (36.73)
270 (53.89)
47 (9.38)

<0.01

(Continued)
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Table 1. Continued.

Characteristics
Immunotherapy initiated
No
Missing
Vital status at last contact
Alive
Deceased

Overall N = 3767
n (%)

African n = 2020
n (%)

Indian n = 1246
n (%)

Mixed n = 501
n (%)

3270 (86.81)
494 (13.11)

1709 (84.60)
310 (15.35)

1109 (89.00)
137 (11.00)

452 (90.22)
47 (9.38)

<0.01

2306 (61.22)
1461 (38.78)

1141 (56.49)
879 (43.51)

842 (67.58)
404 (32.42)

323 (64.47)
178 (35.53)

<0.01

P1

NOS, not otherwise specified. Statistically significant (P <0.05) differences are bolded.
or Fisher’s exact tests were used to derive P-values.
2Geographic area of residence was based on residence within the catchment area of the five Regional Health Authorities (RHAs), which are responsible for the provision of healthcare services in Trinidad and Tobago.
1Chi-square

Table 2. Hazard ratios (HR) and 95% confidence intervals (CI) of mortality in each Regional Health Authority (RHA) catchment area in Trinidad and
Tobago, 1995–2007.
Mortality

NWRHA

ERHA

NCRHA

SWRHA

TRHA

Model
Age-adjusted
Multivariable-adjusted1

1.00 (Ref)
1.00 (Ref)

1.06 (0.83–1.34)
0.98 (0.77–1.24)

0.94 (0.82–1.07)
0.86 (0.75–0.98)

0.80 (0.70–0.91)
0.67 (0.58–0.77)

0.98 (0.76–1.26)
0.98 (0.76–1.27)

Statistically significant (P <0.05) estimates are bolded.
models adjusted for age at incidence, marital status, detection method, cancer stage, and treatment (yes/no). The model was adjusted
for initiation of any treatment.
1Multivariable

Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) of mortality (B) in each Regional Health Authority (RHA) catchment area in Trinidad and
Tobago, by ancestry, 1995–2007.
Mortality
All RHAs
Age-adjusted
Multivariable-adjusted1
ERHA
Age-adjusted
Multivariable-adjusted1
NCRHA
Age-adjusted
Multivariable-adjusted1
NWRHA
Age-adjusted
Multivariable-adjusted1
SWRHA
Age-adjusted
Multivariable-adjusted1
TRHA
Age-adjusted
Multivariable-adjusted1

Indian

Mixed

African

1.00 (Ref)
1.00 (Ref)

0.93 (0.78–1.11)
0.99 (0.83–1.19)

1.31 (1.17–1.48)
1.12 (0.99–1.26)

1.00 (Ref)
1.00 (Ref)

0.48 (0.19–1.17)
0.89 (0.35–2.25)

0.90 (0.55–1.49)
1.01 (0.59–1.74)

1.00 (Ref)
1.00 (Ref)

1.26 (0.90–1.77)
1.12 (0.79–1.58)

1.27 (1.00-1.62)
0.97 (0.75–1.25)

1.00 (Ref)
1.00 (Ref)

0.88 (0.65–1.20)
0.85 (0.63–1.16)

1.46 (1.14–1.87)
1.20 (0.94–1.55)

1.00 (Ref)
1.00 (Ref)

0.74 (0.48–1.15)
0.98 (0.63–1.53)

1.16 (0.94–1.44)
0.91 (0.72–1.15)

1.00 (Ref)
1.00 (Ref)

0.57 (0.09–3.49)
0.36 (0.05–2.53)

0.67 (0.16–2.79)
0.49 (0.12–2.12)

Statistically significant (P < 0.05) estimates are bolded.
1Multivariable models adjusted for age at incidence, marital status, detection method, cancer stage, and treatment (yes/no).

per 100,000) and mortality rates (28.00 per 100,000),
respectively. In SWRHA, incidence and mortality rates

were 38.88 and 14.64 per 100,000. In the SWRHA area,
the corporation of San Fernando had the highest BC

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

incidence (47.12 per 100,000) and Point Fortin demonstrated the highest mortality rate (21.09 per 100,000). In
ERHA, incidence and mortality rates were 34.07 and 15.11
per 100,000; the corporation of Sangre Grande had the
1747
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highest incidence (35.28 per 100,000) and mortality rates
(16.41 per 100,000).
Table 2 shows the HRs and CIs of BC mortality by
geography. After adjustment for age at incidence, marital
status, detection method, cancer stage, and treatment initiation, the mortality rates in the NCRHA (HR 0.86, 95%
CI: 0.75–0.98) and SWRHA (HR 0.67, 95% CI: 0.58–0.77)
were significantly lower than observed in the NWRHA.
We further investigated differences in mortality rates in
each RHA by ancestry (Table 3). Looking within the

W. A. Warner et al.

individual RHAs, compared to women of Indian ancestry,
those of African ancestry had higher mortality rates in
NCRHA (HR 1.27, 95% CI, 1.00–1.62) and NWRHA (HR
1.46, 95% CI, 1.14–1.87).
Unadjusted Kaplan–Meier curves indicate that
BC cases residing in the NWRHA catchment area
had lowest survival probability (5-
year survival, 24%;
10-year survival, 5%). For women in the other RHAs, the
5-year survival rate was 30% and the 10-year survival
rate was <20% (Fig. 2A). Unadjusted Kaplan–Meier

(A)

(B)

Figure 2. Breast cancer survival probability by ancestry (A) and by geography (B) based on residence within Regional Health Authority catchment area.
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curves showed that the African ancestry was associated
with the lowest survival probability over 12.5-
year
follow-

up period, whereas women of Indian ancestry
had the best survival probability up to approximately
year 7.5 with mixed ancestry having the best survival
probability beyond that year. The 5-
year survival
rates for patients of African, mixed and Indian ancestry were 24%, 32%, and 38%, respectively, and the
10-

year rates were 5%, 5.1%, and 8%, respectively
(Fig. 2B).

Discussion
Analysis of ancestral and geographic differences in BC
incidence and mortality rates is an essential component
of understanding the epidemiologic landscape of BC in
TT. In this study, we investigated whether disparities
existed by ancestry and geography for BC incidence, mortality, and survival in TT for the study period 1995–2007.
We observed striking differences in these measures by
ancestry and geography. Most notably, women of African
ancestry had a BC incidence rate that was twice as high
as that observed among women of East Indian and mixed
ancestry. This finding was true in all geographic regions
of TT. Overall, incidence and mortality rates were highest
among residents of the NWRHA catchment area, which
includes the capital city of TT, Port of Spain. Relatedly,
BC cases residing in this geographic area also exhibited
the lowest 5-year relative survival.
It is plausible that the highest BC incidence rates were
observed in the NWRHA geographic area given that the
majority of the public as well as private institutions offering cancer screening, diagnosis and/or treatment services
are located in this catchment area including, the TT Cancer
Society, Port of Spain General Hospital, National
Radiotherapy Centre, the Brian Lara Cancer Treatment
Centre of TT, and Pink Hibiscus Breast Health Specialists.
What may account for the high mortality rates that were
also observed in this area relates to the fact that between
1995 and 2007, the National Radiotherapy Center was
the only public center offering adjuvant and palliative
care, which we hypothesize would have reduced access
to timely treatment among some BC patients. This merits
further study to understand such factors as preventive
care, outreach efforts, medical interventions, in particular
genomic (personalized) medical treatments, and resource
allocation throughout the nation.
In the United States (U.S.), minority women, particularly women of African descent, although having lower
overall BC incidence, are more likely than their white
counterparts to die from their disease, even after accounting for later stage at diagnosis [21–23]. In contrast,
what we have observed among BC cases in TT is that

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Breast Cancer Disparities in Trinidad and Tobago

both incidence and mortality rates were highest among
women of African descent. Similar findings were observed
by Dindyal et al. [24], who analyzed data from the Port
of Spain region of TT specifically and found that the
largest proportion of BC was diagnosed among women
of African descent (54%) followed by women of Indian
descent (35%) and mixed ancestry (11%). Some studies
have suggested that differences in BC incidence and mortality are related to factors related to socioeconomic status
and/or inequity in healthcare access and utilization [25–
29]. While this may be true in the U.S., access to care
is likely not a major concern in TT, given the equal
access to healthcare model in place in the nation. However,
it is quite possible that intrinsic biological variation in
BC exists by ancestry or differences in the distribution
of etiological factors by ancestry may explain some of
the observed disparities in TT [30, 31]. In addition, BC
among women of African ancestry tends to have more
aggressive features [2, 21, 32]. It is unknown whether
this association exists among women in TT, therefore
warranting further study.
The TT cancer registry database captured information
on systemic therapies delivered to BC patients, however
there was no clinical annotation containing hormone
receptor expression status, BC subtype information, or

indication as to whether BC treatment was administered
in the adjuvant setting. A recent study examining BC
treatment and outcomes in TT reported that >50% of
BCs diagnosed between 1995 and 2005 were approximated
to hormone receptor negativity, using receipt of hormone
therapy as a surrogate [16]. Intrinsic subtyping of BC
patients at the time of diagnosis is not routinely done
in TT. It may be that a high prevalence of BCs with
more aggressive features (e.g., hormone receptor negativity,
later stage, higher grade) may contribute to the high
mortality and poor survival rates observed in TT [33,
34]. Given that BC is a heterogeneous disease, it is critical
that molecular subtyping be prioritized in TT as this will
allow for improved patient prognostication and stratification, and personalized treatment [22, 33, 35, 36].
In many higher income countries, there has been a
documented decline or leveling off of BC incidence rates
[37]. In the data from TT, however, we observed an
increase across all demographic groups. These findings
imply a need to improve cancer prevention, screening,
and treatment options, as well as genetics and genomics-
based research. In higher income countries, there is an
increasing shift toward precision medicine, where the
mutational landscape is evaluated to determine the biology
of the tumor, risk of recurrence, and the most appropriate treatment protocol [37]. TT will need to develop a
core genetics and genomics-sequencing infrastructure to
address the local genomic complexity of cancer.
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Our finding of older age at diagnosis among women
of African ancestry suggests that there might be underlying molecular mechanisms playing a central role. This is
consistent with data from Raju et al. [38], which indicated
that carcinoma was observed in only 1.1% of all breast
biopsies among women ≤30 years. Still, almost one-quarter
of incident BCs (22.72%) in this study were diagnosed
at <45 years. It is well established that germline mutations in BC susceptibility genes such as BRCA1, BRCA2,
CHEK2, and TP53 have founder effects leading to increased
risk for cancer incidence and mortality [39–45], particularly
among younger women. Interestingly, there has also been
a documented increase in BC mortality over the past few
decades in TT. Naraynsingh and colleagues[46] showed
that between 1970 and 2004, age-standardized BC mortality had increased from 14.9 per 100,000 to 24.4 per 100,000,
with an increase observed among women <50 years as
well as those ≥50 years. Among women <50 years, mortality rates increased from 3.8 per 100,000 in 1970 to 9.2
per 100,000 in 2004, whereas among women ≥50 years
it increased from 48.6 per 100,000 to 99.4 per 100,000
during the same time period. The high mortality rates,
which are clearly increasing in TT [46], and the observed
disparities by ancestry reported herein suggest that genomic
assessment of the mutational spectra as well as genetic
ancestry analysis is warranted in TT. This is an ideal
environment to examine associations between genetics,
incidence, and disease aggressiveness since there are fewer
disparate mitigating factors.
The observed differences in BC incidence and mortality
by geography may be an indication that differential spatial
access to timely and appropriate care might impact cancer
diagnosis, prognosis, and mortality rates in this Caribbean
setting. Although there is universal healthcare coverage
in TT, patients are required to obtain referrals from a
physician prior to accessing treatment [47]. While there
are no geographic boundaries in TT per se that limit
access to the public medical facilities that provide cancer
care and at minimum, one hospital and several clinics
are located within each RHA catchment area, there are
only four licensed oncologists (none in Tobago) serving
the entire population [48]. Furthermore, the estimated
travel time in TT to an oncology center is between 0.5
and 9 h with <1 h for 26.6% of the population versus
in the U.S. (e.g.,) where it is <1 h for 92% of the population [49]. This might be a major contributing factor to
the geographic disparities. Numerous studies report an
inverse association between travel time and cancer care
[50–55]. However, in TT the highest incidence and mortality rates are in areas closest to cancer centers. Further
examination of the association between spatial access,
distance-and travel time to cancer care facilities, and BC
outcomes in TT is needed.
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This study has some limitations that should be considered in the interpretation of our findings. First, there
were missing data, particularly related to patients’ ancestry,
which highlights the need for more thorough data collection by cancer registry. Another consideration is that
this study was based on retrospective analysis of an anonymous dataset; there was no way to supplement any missing
data. Another limitation of this study was that we did
not evaluate BC screening patterns. Therefore, the observed
disparities in mortality may be due to disparities in screening and possibly treatment, which may be dependent upon
a patient’s place of residence, differences in resource allocation by RHAs and the overall cancer care received.
As a result of this, we cannot verify that cancer patients
seek cancer care at medical centers within their region
of residence, which is another limitation of this study.
Patient demographic information was self-
reported and
may not reflect the entire picture. In particular, ancestry
was self-reported, without the benefit of genomic screening for admixture markers. The absence of data on
reproductive BC risk factors (e.g., age at first birth, and
body mass index (BMI) was also a limitation. The
association between BMI and BC mortality is well established and studies have shown significantly higher BMI
among women of African ancestry, compared to other
racial/ethnic groups [56], which could have contributed
to the differences in BC mortality and survival by ancestry
observed in this study.
Despite limitations, this work has important implications. This study is the first to examine associations among
ancestry, geography, and BC incidence, mortality, and
survival in Trinidad and Tobago. The importance of this
work is underscored by the fact that the BC incidence
and mortality rates are among the highest in the Caribbean
[13–15, 57] and the world even though [1–3] TT has
the largest healthcare budget in the Caribbean. In low-
and middle-
income countries, 18% of BC cases are
attributable to modifiable causes such as alcohol intake,
physical inactivity, and postmenopausal overweight and
obesity [58]. Hence, prevention activities, which incorporate the adoption of a healthier lifestyle, including diet,
could impact BC incidence in TT. Nevertheless, early
detection to improve survival might have the greatest
impact in BC control in TT and efforts to promote such
endeavors are needed. This study also provides an ancestral
and geographical context from which resource allocation
decisions can be made. The findings presented here highlight the need for similar studies in the other Caribbean
island nations. In addition, this study highlights the need
for targeted outreach efforts by ancestry and geography
so as to reduce the documented disparities. Given the
size of Trinidad and Tobago, the disparities reported herein
suggest a need for genetic/genomic studies to determine
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whether these are ancestry-based genomic alterations driving incidence, mortality, and treatment resistance. This
study also highlights the need for research to understand
why the highest rates of incidence and mortality are in
close proximity to cancer centers and biomedical institutions, given that TT has an equal access to care model.
In conclusion, we present evidence that there are
associations between ancestry, geography, and BC incidence,
mortality, and survival in TT. Medical interventions that
seek to improve oncology services nationally will fail to
narrow these disparities since there might exist population-
level social inequalities, and genomic differences, which
can contribute to our findings. Our findings indicate a
need for a national dialog on these disparities and the
deployment of equal access and utilization of quality cancer
care, early detection, genetics and genomics research,
molecular BC subtyping, targeted outreach, and improved
therapeutics to reduce BC disparities.
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